NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc. Investors have until April 15, 2025, to ask the Court to b ...

NEW YORK, March 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of TransMedics Group, Inc. (NASDAQ: TMDX).Shareholders who purchased shares of TMDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/transmedics-group-inc-loss-submission-form-2/?id=137694&from=4 CLASS PERIOD: Feb ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased TransMedics Group, Inc. securities between February 28, 2023, and January 10, 2025, of the April 15, 2025, deadline to become lead plaintiffs in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased TransMedics securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that TransMedics made materially false and misleading statements regarding its business practices, including the use of kickbacks and fraudulent overbilling, which led to regulatory risks and investor damages [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Donor organs make the difference between life and death for thousands of people every year. But there are two big problems. First, far too few donor organs make it to the intended recipients in shape to be used. Second, too many medical issues occur after organ transplants.Enter TransMedics Group (TMDX 0.38%). The company's Organ Care System (OCS) is transforming organ transplantation involving lungs, hearts, and livers by increasing the utilization of donor organs and improving post-transplant clinical out ...

Core Viewpoint - The TransMedics Group, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misconduct including fraudulent practices and safety issues [1][3][4]. Group 1: Allegations Against TransMedics - The lawsuit claims that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate revenue [3]. - It is alleged that the company engaged in unsafe practices and concealed safety issues, lacking proper safety oversight [3]. - The lawsuit cites a letter from U.S. Representative Paul Gosar accusing TransMedics of misconduct, which led to a decline in stock price following its public disclosure [4]. Group 2: Impact on Stock Price - Following the allegations made by Representative Gosar, TransMedics' stock price fell on February 22, 2024 [4]. - A subsequent report by Scorpion Capital on January 10, 2025, accused TransMedics of overbilling and providing rejected organs, which further contributed to a decline in stock price [5]. Group 3: Class Action Process - Investors who purchased TransMedics securities during the specified class period can seek to be appointed as lead plaintiff in the lawsuit [6]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [6]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud cases, having recovered $6.6 billion for investors in class action cases [7]. - The firm has been recognized for securing the most monetary relief for investors and has a significant track record in handling large securities class action recoveries [7].

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for alleged misconduct during the Class Period from February 28, 2023, to January 10, 2025 [1][2]. Allegations Against TransMedics - The complaint alleges that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [2]. - It is claimed that TransMedics practiced unsafe operations, concealed safety issues, and lacked proper safety oversight [2]. - These actions purportedly exposed TransMedics to increased scrutiny and regulatory risks [2]. Lead Plaintiff Process - Investors in TransMedics have until April 15, 2025, to seek appointment as a lead plaintiff representative or may choose to remain absent class members [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or group of investors with the largest financial interest [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/transmed ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against TransMedics Group, Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by April 15, 2025 [2][4]. Group 1: Allegations Against TransMedics - The complaint alleges that TransMedics and its executives made false and misleading statements, failed to disclose the use of kickbacks, fraudulent overbilling, and coercive tactics to generate revenue [4]. - It is claimed that TransMedics engaged in unsafe practices, hid safety issues, and lacked proper safety oversight, which increased regulatory scrutiny and risk [4]. - The lawsuit asserts that the misleading statements about TransMedics' business and operations led to investor damages when the true details became public [4]. Group 2: Market Reaction - Following a report from Scorpion Capital on January 10, 2025, which described TransMedics as a significant healthcare fraud, the company's stock fell by 5.15% on that day and further declined by 6.9% on January 13, 2025 [5]. Group 3: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of the class members, overseeing the litigation on behalf of the class [6]. - Any member of the class can apply to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6]. Group 4: Call for Information - Faruqi & Faruqi encourages individuals with information regarding TransMedics' conduct, including whistleblowers and former employees, to contact the firm [7].

Core Viewpoint - A class action securities lawsuit has been filed against TransMedics Group, Inc. for alleged securities fraud affecting investors between February 28, 2023, and January 10, 2025 [1][2] Group 1: Allegations - The lawsuit claims that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [2] - It is alleged that the company engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight [2] - The aforementioned actions reportedly subjected TransMedics to increased scrutiny and regulatory risks, leading to materially false and misleading statements about its business and operations [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until April 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Editor's note: Seeking Alpha is proud to welcome LW Research as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.LW Research is run by a qualified accountant working in the financial services sector mainly in private equity, hedge funds, asset management and venture capital. Since my time working as an accountant I've become extremely well versed at divin ...